Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by UMB Bank n.a.

UMB Bank n.a. grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 41.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 109 shares of the medical research company’s stock after purchasing an additional 32 shares during the period. UMB Bank n.a.’s holdings in Bio-Rad Laboratories were worth $36,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Van ECK Associates Corp grew its position in shares of Bio-Rad Laboratories by 97.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock worth $436,861,000 after acquiring an additional 644,530 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Bio-Rad Laboratories during the 3rd quarter valued at $83,681,000. Wedge Capital Management L L P NC acquired a new position in Bio-Rad Laboratories during the fourth quarter worth about $28,740,000. Mawer Investment Management Ltd. increased its holdings in shares of Bio-Rad Laboratories by 63.0% in the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after buying an additional 84,237 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Bio-Rad Laboratories by 38.3% during the third quarter. The Manufacturers Life Insurance Company now owns 86,782 shares of the medical research company’s stock valued at $29,036,000 after purchasing an additional 24,052 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Price Performance

Shares of BIO opened at $356.25 on Friday. The company has a 50 day moving average of $336.56 and a 200-day moving average of $333.06. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $9.98 billion, a P/E ratio of -13.04 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business had revenue of $649.70 million during the quarter, compared to analysts’ expectations of $628.18 million. During the same quarter in the previous year, the company earned $2.33 EPS. The business’s revenue was up 2.8% on a year-over-year basis. As a group, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BIO. Citigroup raised their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Royal Bank of Canada restated an “outperform” rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $394.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.